Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mk-0873. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 14/20 | 1.00 |
| ▸ | PDE4B known ✓ | Q07343 | 13/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 13/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 13/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 8/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-0873 SCHEMBL29496418 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| Mk-0873 SCHEMBL29372259 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL12198465 | 0.91 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL5337172 | 0.87 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL717406 | 0.86 | KCNH2 (1.00) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL12995884 | 0.86 | KCNH2 (0.81) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL2331333 | 0.85 | KCNH2 (0.79) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL1566354 | 0.84 | KCNH2 (0.77) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL17233514 | 0.84 | KCNH2 (0.73) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL1566248 | 0.83 | KCNH2 (0.76) | PDE4APDE4BPDE4CPDE4DKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | claimed |
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-08-17 | — | — | US | claimed |
| EP-3185903-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | Fundación para la Investigación Médica Aplicada (ES) | 2017-07-05 | — | — | EP | claimed |
| WO-2016030345-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-03-03 | — | — | WO | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | disclosed |
| EP-3984555-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2022-04-20 | — | — | EP | disclosed |
| EP-3785733-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2022-01-05 | — | — | EP | disclosed |
| US-20210154177-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2021-05-27 | — | — | US | disclosed |
| US-20210145803-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2021-05-20 | — | — | US | disclosed |
| US-10940140-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2021-03-09 | — | — | US | disclosed |
| EP-3498297-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2019-06-19 | — | — | EP | disclosed |
| US-8796452-B2 | Preparation of lamivudine form I | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130231363-A9 | ALTERNATIVE FORMS OF THE PHOSPHODIESTERASE-4 INHIBITOR N-CYCLOPROPYL-1--4-OXO-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXYAMIDE | MERCK SHARP & DOHME LLC | 2013-09-05 | — | — | US | disclosed |
| US-20120316339-A1 | Preparation of Lamivudine Form I | MERCK SHARP & DOHME LLC | 2012-12-13 | — | — | US | disclosed |
| US-20110245290-A1 | Alternative Forms of the Phosphodiesterase-4 Inhibitor N-Cyclopropyl-1--4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide | CLAS SOPHIE-DOROTHEE | 2011-10-06 | — | — | US | disclosed |
| WO-2009052624-A9 | INHALATION COMPOSITIONS COMPRISING MONTELUKAST ACID AND A PDE-4 INHIBITOR OR AN INHALED CORTICOSTEROID | MERCK FROSST CANADA LTD. (CA) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009052624-A1 | COMBINATION THERAPY | MERCK FROSST CANADA LTD. (CA) | 2009-04-30 | — | — | WO | disclosed |
| US-20080119509-A1 | Altenrative Forms Of The Phosphodeisterase -4 Inhibitor N-Cyclopropyl-1- -3{3-[(1-Oxidopyryidin-3-Yl) Phenyl]-4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide | MERCK CANADA INC. (CA) | 2008-05-22 | — | — | US | disclosed |
| US-20070071692-A1 | Aerosol powder formulation | MERCK FROSST CANADA LTD. (CA) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | SNCA, PSEN2, PSEN1 | PDE4A 1415/4885PDE4B 1380/4885PDE4C 1669/4885 |
| US-20080119509-A1 | Altenrative Forms Of The Phosphodeisterase -4 Inhibitor N-Cyclopropyl-1- -3{3-[(1-Oxidopyryidin-3-Yl) Phenyl]-4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide | TPI1, ENPP1, SMPD4 | PDE4A 16/4885PDE4B 25/4885PDE4C 49/4885 |
| US-20070071692-A1 | Aerosol powder formulation | PDE12, PDE4A, PDE4D | PDE4A 2/4885PDE4B 4/4885PDE4C 5/4885 |
| US-20120316339-A1 | Preparation of Lamivudine Form I | TYMP, TYMS, CTDSP1 | PDE4A 4254/4885PDE4B 4476/4885PDE4C 3790/4885 |
| US-20130231363-A9 | ALTERNATIVE FORMS OF THE PHOSPHODIESTERASE-4 INHIBITOR N-CYCLOPROPYL-1--4-OXO-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXYAMIDE | PDE4A, PDE4B, PDE3B | PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885 |
| US-20110245290-A1 | Alternative Forms of the Phosphodiesterase-4 Inhibitor N-Cyclopropyl-1--4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide | PDE4A, PDE4B, PDE3B | PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.